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Abstract 
Purpose: To investigate potential cytotoxic T-lymphocyte antigen-4 (CTLA-4) binding partners and 
assess whether potential binding partners affect the full function of CTLA-4. . 
Methods: The down-regulation effects of CTLA-4 and SIT were assessed by culturing CD3 stimulated 
T-cells. CTLA-4 and SIT proteins were measured by immunoblot analysis and production of interlukin-2 
transcription activity evaluated by luciferase assay.  
Results: CTLA-4 inhibited the interlukin-2 production capacity of CD3-stimulated T cells.  CTLA-4 
interaction with SHP2 interacting transmembrane adapter protein (SIT) in the down-regulation of the 
transcription of Interulin-2 required CTLA-4 binding to SIT tyrosine motifs. The SIT tyrosine mutants 
were significantly lower (25 – 75 %) after phosphorylation compared with WT-SIT (transfected cells, p < 
0.05) and untreated control. The remaining 90 % phosphorylation in the F188ANS mutant can be 
explained by phosphorylation of other tyrosines in the sequence of SIT (p < 0.05).  For interukin-2 
transcription, F188ANS single mutant and double F148SEV mutant, increased NF-AT activity by 35 % 
compared with the wild type (p < 0.05). 
Conclusion: The findings imply that SIT transmembrane adaptor (SIT) protein, binds to CTLA-4 and 
thus potentiates the inhibitory role of this co-receptor. This phenomenon may lead to the development of 
new treatment strategies for autoimmune diseases and graft rejection. 
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CTLA-4 signaling is well-documented in its ability 
to downregulate T-cell proliferation and cytokine 
production [1,2]. Studies using CTLA-4 
antibodies have shown that CTLA-4 blocks T-cell 
proliferation, IL-2 production and NFAT 
translocation into the nucleus, implying that its 
general effects downplay the immune response 
[3]. An in vivo study of CTLA-4 knockout mice 
had tissue destruction by the immune system 
and extensive lymphadenopathy [4].  
 
The full activation of naïve T-cells depends on 
two signals that ignite proliferation, differentiation 
and cytokine secretion [2]. The first is provided 
by the T-cell receptor (TcR) upon recognition of a 
specific antigenic peptide in complex with a MHC 
class II molecule. The second signal is delivered 
by the T-cell’s co-stimulatory receptors upon 
ligation of their counterparts by antigen 
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presenting cells (APC). The balance between 
signaling of the major co-stimulatory molecules 
CD28 (the positive co-receptor) and CTLA-4 (the 
negative co-receptor) determines the outcome of 
immune response [5].   
 
Transmembrane adaptor proteins (TRAPS) 
facilitate precise signal transduction by forming 
specific protein complexes [5]. Unlike kinases, 
which use enzymatic and transcriptional activity 
to promote signaling, TRAPS act as scaffolds 
and recruit molecules for detailed intracellular 
signaling complexes [6]. Recently, our laboratory 
found that a small TRAP, SIT, binds to CTLA-4 
and enhances CTLA-4 surface expression [6]. 
SIT is a disulfide-linked homodimeric polypeptide 
which is exclusively expressed in lymphocytes. In 
contrast to the other transmembrane adaptor 
proteins known so far, SIT is a heavily 
glycosylated polypeptide [13]. This could indicate 
that SIT possesses an external ligand that 
modulates its function. This study was conducted 
to understand the molecular mechanisms leading 





Cells and reagents 
 
Jurkat T-cells (ATCC, American Type Culture 
Collection, VA, USA )  were cultured in RPMI 
1640 supplemented with 5 % fetal calf serum 
(FCS), 2 mM L-glutamine and 100 U/ml 
penicillin/streptomycin [7].  Anti-CD3 (OKT3) was 
obtained from the ATCC and anti-human CTLA-4 
mAb was provided by Dr. Broeker (Greifswald, 
Germany). Anti-HA antibody was purchased from 
Covance Research Product Inc.  
 
Plasmid DNA cloning 
 
Full-length human SIT-R cDNA PCR primer 
sequences were 5-gctctagagccaccatg-3 sense 
and 5-tgacacgccaagcttggtac-3 antisense. PCR 
contained five cycles of 60 s at 94 ºC, 30 s at 37 
ºC and 60 s at 72 ºC and a further 25 cycles 
within an annealing temperature of 45 ºC. The 
amplified products were ligated into the TA 
cloning vector (Invitrogen) and confirmed by DNA 
sequencing.  
 
Immunoprecipitation and immunoblotting  
 
Cells were lysed in an ice-cold lysis buffer 
containing 1 % Triton X-100 in 20 mM Tris-HCl, 
pH 8.3, 150 mM NaCl, protease inhibitors, and 
phosphatase inhibitors. Post-nuclear lysates 
were incubated for 1 h with the indicated 
antibody. Protein A-Sepharose beads (30 µl, 
Amersham Pharmacia) were added and 
incubated for 1 h at 4 ºC. The eluted proteins 
were separated by 10 % SDS-PAGE and 
transferred to a nitrocellulose membrane for 
immunoblotting. The membranes were blocked 
with 5 % milk in TBS (10 mM Tris-HCl, pH 7.6, 
150 mM NaCl) and incubated with their 
corresponding antibodies. A secondary antibody, 
provided by Amersham (NJ, USA), allowed the 
first antibody to be observed by enhanced 
chemiluminescence (ECL). 
 
Interleukin-2 luciferase assay 
 
Jurkat T-cells were co-transfected with 10 µg of 
corresponding cDNA and combined with 2 µg of 
pNFAT3-Luc plasmid or 0.1 µg of a control 
reporter plasmid (pRL-TK from Promega). Cells 
were pulsed using BTX Gene Pulser at 260 V, 
960 F in 10 % Fetal Calf Serum. Cells (1 × 107 
cells) were aliquoted in a 96-well plate 18 hrs 
after transfection and cultured in a final volume of 
200 µL of RPMI 1640 growth medium. After 5 h 
stimulation by CD3 (145-2C11; 2 µg/mL), 
CD3/rabbit anti-mouse (2 µg/mL) antibodies, or 
rabbit anti-mouse antibodies alone (which served 
as negative controls), cells were lysed in 100 µL 
of lysis buffer (Promega kit, Promega, WI, USA). 
Luciferase activity was quantified using a 
luminometer (MicroLumat, EG7G Berthold) 
immediately after addition of 100 µL luciferase 
substrate (Promega kit) and a Stop and Go 
reaction to control amounts of reporter plasmid 
(dual luciferase system kit from Promega, WI, 
USA). Luciferase units of the experimental vector 
were normalized to the level of the control vector 




Data are presented as mean ± SEM (n = 3). 
Statistical analysis was performed with a 
statistical software (SAS Institute, Cray, NC, 
USA) using one-way analysis of variance, 
followed by Dunnett's multiple range tests. P < 




Identification of the SIT tyrosine 
phosphorylation 
 
Fig 1A shows the amino acid sequence of a 
portion the potential tyrosine phosphorylation 
motifs that would be suited for SH2 domain 
binding. The cytoplasmic domain of SIT carries a 
total of five potential sites of tyrosine 
phosphorylation. These are Y90GNL, Y128TSL, 
Y148SEV, Y168ASV and Y188ANS. To assess 
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which of these five tyrosines represent 
phosphorylation sites, we generated a series of 
SIT mutants.  
 
To determine whether the tyrosine base motifs 
are sites of phosphorylation, wild-type SIT (WT 
SIT) and SIT mutants were expressed in Jurkat T 
cells,  the cell were activated 2 min with 
pervanadate and were assessed for 
phosphorylation by anti-phosphotyrosine blotting 
(Fig. 1B, upper panel). The F90GNL and F168ASV 
single mutants were significantly less 
phosphorylated when compared with WT SIT 
(lane 3 and 6 vs 2). Phosphorylation was 
reduced even further (generally < 90 % of WT) in 
the F188ANS (lane 7; also see histogram in Fig. 
1C). As an internal control for expression, anti-
SIT Ab detected similar levels of expression for 
SIT and the mutants (Fig. 1B, lower panel). 
These data demonstrate that F90GNL, F168ASV 
and F188ANS are major sites of phosphorylation 
by pervanadate. The remaining 90 % 
phosphorylation in the F188ANS mutant can be 
explained by protein tyrosine kinase 
phosphorylation of other tyrosines in the 
sequence of SIT. 
 
SIT tyrosine based motifs are necessary for 
CTLA-4 binding 
 
To assess whether the tyrosine sites are 
responsible for binding to CTLA-4, the SIT 
mutants (F90GNL, F128TSL, F148SEV, F168ASV 
and F188ANS) were co-expressed with CTLA-4 in 
Jurkat T cells followed by immuno-precipitation 
with anti-CTLA Ab and anti-SIT blotting. The 
expression levels of SIT and the mutants and 
CTLA-4 were similar as shown in the whole-cell 
lysates (Fig. 2A, right upper and lower panels, 
respectively). As expected, CTLA-4 co-
precipitated WT SIT (left panel, lane 1), whereas 
the mutant F90GNL, F148SEV, F188ANS fail to co-
precipitate with CTLA-4. 
 
The single mutations resulted in significant 
reductions in CTLA-4 binding, with Y188ANS 
having a greater effect (90 % reduction) than 
Y148SEV (85 % reduction) (left panel, lanes 5 and 
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Figure 1: Identification of major sites of SIT phosphorylation by pervanadate in T cell. The tyrosines 128 and 148 
are phosphorylated by pervanadate in Jurkat cells. A =The mutants of SIT created for these studies with 
phenylalanine (F) replacing tyrosine (Y) in the underlined region. B = cDNA wild type SIT (lanes 1 and 2) and SIT 
mutants (lanes 3–6) were transfected alone into Jurkat cells. Then, 18 h after transfection, lysates were prepared 
in 1% Triton X-100 lysis buffer, subjected to SDS-PAGE, and immunoblotted with anti-pTyr Ab (upper panel) or 
anti-SIT Ab (lower panel). Positions of molecular mass markers (kDa) are indicated. C, Densitometric analysis 
using the Scantjet laser scanner (Hewlett-Packard) of anti-pTyr binding to SIT (B, upper panel). Values were 
standardized with anti-SIT binding to SIT (B, lower panel). The data were normalized tothe control cells. Data are 
expressed as the mean ± SD (n = 5). Transfected cells (p < 0.05) compared to untreated control 
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SIT and CTLA-4 interaction is required to 
downregulate IL-2 transcription activity  
 
To address the role of CTLA-4 binding to SIT in T 
cell function, Jurkat T cells were transiently 
transfected with SIT mutants or a control vector 
together with CTLA-4 and a luciferase reporter 
construct driven by an IL-2 NF-AT/AP-1 
promoter. The combined expression of F188ANS 
SIT mutant /CTLA-4 potentiated IL-2 transcription 
by about 35-fold beyond vector-transfected 
control (Fig 3).  
 
By contrast, the F128TSL and F148SEV had little 
effect on with CTLA-4.  WT experiments showed 
no effect. This limited interaction may be 
sufficient to mediate the down-regulation of TCR-
stimulated NF-AT/AP-1 activity. 
 
Analysis of the SIT mutants indicate that SIT-
CTLA-4 interaction is crucial in the down-
regulation of T cell pathway, as a marked 
enhancing of NF-AT/AP-1 activity was observed 
in transfectants expressing the mutants 
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Figure 2: (A) Comparison binding analysis of = SIT mutants with CTLA-4. Then, 18 h after transfection, cells 
were lysed and precipitated with anti-SIT Ab. Anti-SLP-76 immune complexes (lanes 1–6)  and cell lysates (A. 
left pannel, lanes 1–6) and were subjected to SDS-PAGE and blotted with anti-SIT and anti-CTLA-4. Positions of 
molecular mass markers (kDa) are indicated. Lanes 1, cells transfected with WT SIT; lanes 2, F90GNL; lanes 3, 
F128TSL; lanes 4, F148SEV; lanes 5, F168ASV; lanes 6, F188ANS. (B) Densitometric analysis using the Scantjet 
laser scanner (Hewlett-Packard) of SIT bound to CTLA-4 (A, left panel). The data were normalized to the control 
cells. Data are expressed as the mean ± SD (n = 5). Transfected cells (p < 0.05) compared to untreated control 
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The enhancing was greatest with the F188ANS 
single mutant and the double F148SEV mutant, 
enhancing the NF-AT activity by 30–35 % 
























Figure 3: CTLA-4/SIT-R complex completely inhibited 
IL-2 gene transcription. Luciferase units of the 
experimental vector were normalized to the level of the 
control plasmid in each sample. The data were 
normalized to the control cells. Data are expressed as 
the mean ± SD (n = 5). Transfected cells (p < 0.05) 




CTLA-4 plays an important role in mediating T-
cell function, but little is known regarding the 
mechanisms behind this response.  Thus, a 
better understanding of the molecular 
mechanism of CTLA-4 will allow researchers to 
develop therapeutic approaches to reverse the 
adverse impact of CTLA-4 dysfunction and 
harness the immune response.  
 
Reported mechanisms include competition for 
CD28 binding to CD80 and CD86 [8], disruption 
of CD28 localization at the immunological 
synapse [9], binding to phosphatases PP2A and 
SHP-2 and interference with lipid raft expression 
[10]. In contrast to CD28, which is found on 
resting and activated cells, CTLA-4 is only found 
on activated cells. It is primarily an intracellular 
antigen whose surface expression is tightly 
regulated [11]. This tight regulation is achieved 
by controlled trafficking to the cell surface and 
rapid internalization. Even at its highest amounts, 
surface expression of CTLA-4 is only at about 3 
percent of the time CD28 (the positive co-
receptor) is expressed [12]. 
 
During the past few years, several TRAPs 
involved in the relay signaling have been 
identified including LAT (linker for activation of T-
cells), SIT (SHP2 interacting transmembrane 
adaptor protein), LAX (lck interacting membrane 
protein), LIME (lck interacting membrane 
protein), NTAL/LAB (T-cell activation linker/linker 
for activation of B-cells) and PAG/Cbp 
(phosphoprotein associated with 
glycosphingolipid-enriched microdomains/CSK 
binding protein) [13].  Recently, the small 
transmembrane adaptor protein T cell receptor-
interacting molecule (TRIM) was found to bind to 
CTLA-4 leading to enhanced CTLA-4 surface 
expression [7].  
 
SIT-R is capable of binding to CTLA-4 in T-cell. 
This identification of SIT binding to CTLA-4 
increases the number of proteins known to bind 
CTLA-4, and possibly suggests that SIT and SIT-
R will act in a negative signaling cascade. From 
our observations, it appears that in T cells both 
Tyr148 and Tyr188 are essential for optimal binding 
of CTLA-4.  
 
The regulation of CTLA-4 function by interaction 
with SIT may serve as a possible accessory 
immunomodulatory molecule for optimizing T-cell 
function. In addition, the absence of CTLA-4 has 
been shown to result in organ destruction, 
lymphoproliferative disease and numerous 
autoimmune diseases in human including 
diabetes. On the contrary, an excessive 
decrease in T-cell mediated immune reaction by 




The findings of this study show that TRAP, 
termed SIT transmembrane adaptor (SIT) 
protein, binds to CTLA-4 and potentiates the 
inhibitory role of this co-receptor. SIT-R plays an 
important role in the functions of CTLA-4, and 
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